Telesis Bio (NASDAQ:TBIO) Shares Down 2.4% – Time to Sell?

Telesis Bio, Inc. (NASDAQ:TBIO) shares dropped 2.4% during mid-day trading on Thursday . The company traded as low as $0.41 and last traded at $0.41. Approximately 423 shares traded hands during trading, a decline of 92% from the average daily volume of 5,125 shares. The stock had previously closed at $0.42.

Telesis Bio Stock Down 2.4 %

The firm’s fifty day simple moving average is $0.61 and its 200-day simple moving average is $2.24. The company has a market cap of $729,800.00, a PE ratio of -0.01 and a beta of 1.64.

Telesis Bio (NASDAQ:TBIO) last posted its earnings results on Thursday, November 7th. The company reported ($3.83) earnings per share (EPS) for the quarter. The company had revenue of $1.57 million during the quarter.

About Telesis Bio

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.